As a founder, you know that growth depends on investor confidence as much as innovation.
Each funding round, disclosure and milestone announcement carries legal weight because your valuation is built on past results and future projections, not guarantees. That structure makes your company inherently exposed to securities litigation when expectations, disclosures or market reactions turn contentious.
A securities dispute arises when someone challenges the communications or mechanics related to the offer, sale, purchase or ownership of your company’s securities.
The claim typically alleges that your company:
Life sciences and other technology companies are particularly prone to securities disputes because of the way their businesses grow and raise capital. Your company probably moves fast, depends on large infusions of investor funding and builds value around forward-looking milestones. That combination of speed, uncertainty and reliance on projections creates the environment where securities disputes often begin.
The first source of securities disputes often arises when regulatory setbacks reduce a company’s market value. Common examples include:
When events like these occur, investors may respond by filing a class action lawsuit claiming that the company misled the market about the risk beforehand. The allegation typically centers on earlier statements that appeared optimistic or incomplete in light of the later setback.
Disclosure is the currency that drives investor confidence. In the startup world, investors frequently buy based on your future milestones, not just your current performance, which means every statement you make about progress, risk or timelines carries legal weight. When your internal information changes but your public statements do not, that gap can become the foundation for a securities dispute.
For example, you may tell investors that a clinical trial is “on track,” a software rollout will “launch next quarter” or an FDA filing is “expected later this year.” At the time, those statements reflect what you know. But conditions can shift quickly:
If the company continues using prior optimistic statements without updating investors, plaintiffs’ attorneys may later argue that the omission was misleading. Once the setback becomes public and the market reacts, those outdated assurances are used to claim that the company misrepresented risk.
Promotional or investor relations statements can create securities exposure when they overstate readiness, approval status or revenue potential. Your company’s marketing or investor relations team might describe a product as “FDA-cleared,” “market-ready,” or “generating strong early demand.”
In most cases, such statements are meant to build enthusiasm, not deceive. But when the underlying facts do not yet support those claims, the language can become a source of future litigation.
Investors often rely on these public statements when deciding whether to buy shares or participate in a financing round. Because those statements shape valuation and perception, any gap between promotion and fact can lead to claims of misrepresentation once conditions change. Common turning points include:
When these events occur, investors may file a class action lawsuit alleging that the company’s earlier promotional materials misled the market. What began as a marketing effort can quickly become a securities dispute if investors argue that the company overstated progress or omitted material risk.
Crowley Law LLC advises founders and executives in life sciences and other technology companies on how to prevent, manage and resolve securities disputes. We help clients identify areas of exposure early, strengthen their disclosure and governance practices and respond effectively when claims are filed.
We handle matters such as:
Our team combines securities law insight with practical knowledge of how life sciences and other technology businesses operate.
The best time to seek legal guidance is before issues escalate. Our firm advises founders during investor discussions, regulatory filings and funding rounds to help them stay ahead of potential disputes.
You should reach out before any dispute escalates — ideally when preparing for a new funding round, updating investor materials or responding to regulatory inquiries. Early guidance helps align your disclosures with legal obligations and minimize risk before litigation begins.
A securities dispute specifically involves the offer, sale or ownership of your company’s securities, such as stock, SAFEs or convertible notes. These cases often focus on alleged misrepresentation, omission or breach of investor rights rather than operational or contractual issues.
Most start with a sudden stock drop or negative development, such as failed clinical results or delayed product launches, followed by investor claims that earlier company statements were misleading. Plaintiffs’ attorneys then use those statements to allege securities fraud or disclosure violations.
Private companies are also exposed. Misrepresentation claims can arise during private placements, SAFEs or convertible note financings when investors allege they relied on inaccurate or incomplete information before investing.
The foregoing analysis is for educational purposes only and does not constitute legal advice. You should engage an experienced lawyer to help you deal with any issues of this type as they apply in your unique situation.
